FOXP3 and autoimmune disease: Finally, we expressed miniF5111 IC from engineered Tregs and showed that stable expression of this molecule led to prolonged cell persistence and sustained FOXP3 expression following adoptive transfer.<h4>Discussion</h4>Taken together, our findings position miniF5111 IC as a versatile platform to selectively target and activate specific immune cell subsets, demonstrating its potential as a next-generation therapeutic to treat autoimmune disorders and prevent transplant rejection.